METABOLOMICS AIDS IN UNDERSTANDING MECHANISMS OF COMMONLY USED DRUGS
New Research Seeks to Understand Toxicological Effects of Fenofibrate
RESEARCH TRIANGLE PARK, N.C. (August 12, 2009) — Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, today announced a new study has been published which seeks to better understand the toxicological uncertainties of fenofibrate. Co-authored by Metabolon and Mitsubishi Tanabe Pharma, "Untargeted Metabolomic Profiling as an Evaluative Tool of Fenofibrate-Induced Toxicology in Fischer 344 Male Rats" appears in Toxicologic Pathology (Vol. 37, No. 4, 521-535, 2009).
"Complete mechanistic understanding of the full effects of fibrate action is still quite limited,” explained Naohisa Tsutsui, one of the authors of the paper from Mitsubishi Tanabe Pharma. “In this study, we applied global biochemical profiling as a means to gain further insight into the molecular mechanisms of fenofibrate and better understand its pharmacology and toxicology. This technology offered us a valuable tool in the process of new hypothesis generation."
A widely-used drug, fenofibrate belongs to the fibrate class of drugs that have been used to treat patients with a variety of metabolic disorders and is often a preferred therapy in combination with statins to treat people with dyslipidemia. While fenofibrate is considered safe in humans, it is known to have toxicological effect in rodents. This study was an investigation of the efficacy and toxicological effects of this class of drugs in rodents.
"The toxicological concerns surrounding this class of drugs and a true understanding of their mechanisms has long been an area of intensive research," said Lining Guo, senior director and head of commercial operations with Metabolon. "This study found significant biochemical effects of fenofibrate treatment in rodents that demonstrates the power of a non-targeted metabolomics approach."
Click here to read the complete abstract of the publication
Metabolon is a diagnostics and services company offering the industry’s leading biochemical profiling platform. Metabolon’s patented platform provides a global analysis of complex biological samples for the discovery of markers and pathways associated with drug action and disease. This metabolomics-driven approach enables the identification of biomarkers useful for the development of a wide range of diagnostics and provides insight into complex biochemical processes such as drug action, toxicology and bioprocess optimization. For more information about Metabolon, please visit www.metabolon.com.